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Abstract
Background: This study aimed to investigate the possible apoptotic role of bortezomib (BMZ) on pancreatic islets of
streptozotocin (STZ)-induced diabetic rats.
Methods: Sprague-Dawley rats were divided into groups that were administered BMZ alone or in combination with STZ. To
evaluate the effect of BMZ on the development of diabetes, blood glucose levels were measured regularly in the animals. Islet cell
viability was determined by staining the islets with fluorescein diacetate and propidium iodide. Expression of the Bcl-2 and bax
genes was determined in islet cells by quantitative real-time polymerase chain reaction.
Results: Administering STZ-induced hyperglycemia in the rats reduced the viability of islet cells and the bcl-2/bax ratio. In the
group administered BMZ alone, the bcl-2/bax gene expression rate in islets increased significantly compared to the control
group. BMZ co-administered with STZ significantly increased islet cell viability and the bcl-2/bax ratio compared to the diabetic
group.
Conclusions: This study demonstrates that BMZ may protect pancreatic islet cells from apoptosis by increasing islet viability and
upregulating the bcl-2/bax gene expression ratio, even though it failed to protect against the destructive effect of STZ.
Keywords: apoptosis, bortezomib, pancreatic islets, rats, type 1 diabetes

INTRODUCTION

Bortezomib (BMZ) is a proteasome inhibitor approved by
the Food and Drug Administration for use in the
treatment of multiple myeloma and mantle cell
lymphoma. BMZ is a potent inhibitor of the NF-κB
pathway.8 It inhibits the activation of NF-κB by blocking
the proteasomal degradation of IκB and inducing
apoptosis in many tumor cell types in preclinical
studies.8,9 However, the exact mechanism of how BMZ
affects pancreatic islet cell apoptosis remains unclear. A
recent study showed that BMZ regulates the immune
system in autoimmune diabetes and reported that
administering BMZ to pre-diabetic non-obese mice
prevents the development of diabetes in 80% of the
mice, while it did not show any therapeutic effect when
administered alone to overtly diabetic mice.10 In addition,
BMZ reduced islet rejection in another study where BMZ
was systemically administered to STZ-induced diabetic
mice before islet transplantation.6 In both studies, it was
suggested that BMZ prevented the development of
diabetes due to its anti-inflammatory properties, but the
apoptotic process in the islets has not been investigated.
Other proteasome inhibitors induce apoptosis in mouse
and rat beta insulinoma cell lines,11,12 but the
proteasome inhibitors containing MG-132, celastrol and
epoxomicin, lactacystin, and N-Acetyl-Leu-Leu-Nle-CHO
(ALLN) have quite contradictory results such as reducing,
increasing, or no effect on rat islet viability.11,13,14 The
purpose of this study was to investigate the apoptotic

Type 1 diabetes is an autoimmune disease characterized
by selective and progressive destruction of insulinsecreting beta cells of the pancreas.1 The nuclear factor
kappa B (NF-κB) signaling pathway plays a role in the
development of diabetes.2,3 NF-κB is a transcriptional
factor that transcriptionally activates the genes required
for important biological processes, such as cell
proliferation, apoptosis, survival, and inflammation.4,5
Most studies that have shown the role of NF-κB activation
in pancreatic beta cell death indicate that NF-κB has a
predominant
pro-apoptotic
function.2,6
However,
activation of NF-κB is generally considered to be antiapoptotic and pro-oncogenic in many tumor types.
Therefore, blocking NF-κB activation is a successful target
therapy for cancer treatment.4,5 Blocking NF-κB activation
directly with chemical inhibitors or transgenic animal
models results in resistance to STZ-induced development
of diabetes, decreased inflammation, and increased
survival of islet grafts in transplantation experiments.6,7
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effects of BMZ on rat pancreatic islet cells in STZ-induced
diabetes using in vivo and in vitro experiments.
METHODS
Ethical approval
All procedures were conducted following the accepted
principles for the care and use of laboratory animals and
were approved by the Local Ethical Committee of
Laboratory Animals at Diskapi YB Education and
Research Hospital, Ankara, Turkey (Protocol no: 2016/05).
Animals
Female Sprague-Dawley rats (average weight, 200–250 g;
age, 4–6 months old) were used to investigate the effect
of BMZ on the development of type 1 diabetes. All
animals were housed in a special pathogen-free and
temperature-controlled room (21 ± 2 °C) with a 12 h
light/12 h dark cycle. The rats were fed a standard
pelleted diet and water ad libitum. All animal
experiments were performed following the Guide for the
Care and Use of Laboratory Animals (NIH Publications
No. 80–23) and approved (2016/05) by the Ethical
Committee of Laboratory Animals at YB Teaching and
Research Hospital, Ankara, Turkey.
STZ-induced diabetic rat model
The STZ-induced diabetes rat model was used to
determine the apoptotic effect of BZM on pancreatic
islets. The rats were randomly selected and divided into
four groups: 1) Control, 2) STZ group, 3) BZM group, and
4) STZ + BZM group (n = 10). Diabetes was induced in the
rats by a single intraperitoneal injection of STZ (SigmaAldrich, St. Louis, MO, USA) at a dose of 45 mg/kg in
freshly prepared citrate buffer (50 mM sodium citrate,
pH 4.5).15 The control group was administered citrate
buffer alone. BMZ (0.2 mg/kg, Milenium Pharmaceutical,
Cambridge, MA, USA) was injected intraperitoneally 3
times (days 1, 4, and 8) in all related groups as described
previously.16 The first BMZ dose was administered to the
STZ+BZM group 2 h before the STZ injection (day 1).
Then, the other two BMZ doses were injected as in the
BZM group (days 4 and 8). All rats were anesthetized by
intraperitoneal injection of a mixture of ketamine and
xylazine on day 10, and the pancreas was removed.
Blood glucose levels and body weight were measured
before the drugs were administered and every other day
after the injections. Blood glucose levels were detected in
the tail vein blood of all rats using the Accu-check blood
glucose meter (Bayer Corp., Whippany, NJ, USA). Rats
with blood glucose levels > 250 mg/dL were defined as
diabetic.
Isolation and purity of the islets
The islets were isolated as described previously.17 Briefly,
the pancreas was inflated by injecting 7 ml of cold
collagenase type V solution (1 mg/ml) into the bile ducts
Makara J Health Res.
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of the rats. The pancreas was removed, and the islets were
separated by Ficoll density centrifugation. After isolation,
the islets were hand-picked under a stereomicroscope.
The number and purity of the islets were determined by
counting after diphenylthionarbazon (DTZ; Sigma-Aldrich)
staining in which islets were dyed scarlet at 37 °C for 10
min. After adding 50 mM BMZ to the culture medium of
the BZM and STZ + BZM groups, all islets were cultured
at 37 °C in humidified air and 5% CO2 in RPMI-1649
medium supplemented with 1% L-glutamine, 10% heatinactivated fetal bovine serum (Sigma-Aldrich), and a 1%
antibiotic mixture (100 units/mL of penicillin and 100
𝜇g/mL of streptomycin; GIBCO, Grand Island, NY, USA)
overnight in 25 cm2 flasks.
Islet viability
The viability of 3–5 islets collected from each rat was
analyzed by dual fluorescent staining consisting of
fluorescein diacetate (FDA) and propidium iodide (PI)
(Sigma-Aldrich).18 The percentage of viable islets was
obtained from the ratio of living cells stained green with
FDA to dead cells stained red with PI. Stained islet cells
were visualized with a fluorescent microscope (Olympus
CX-41: Tokyo, Japan), and the mean viability values were
determined using the MatLab color analysis program
(MathWorks Inc., Natick, MA, USA).
Real-time quantitative polymerase chain reaction
(RT-PCR)
Total RNA was isolated from the cultured islets of each
rat using the PureLink RNA Mini kit (Ambion Corp.
Naugatuck, CT USA), following the manufacturer’s
instructions. RNA concentration and purity were
determined with the Thermo NanoDrop2000 (ThermoFisher Scientific, Waltham, MA, USA), and sample
integrity was assessed by gel electrophoresis. A 1 µg
portion of total RNA was reverse-transcribed using the
Applied Biosystems High-Capacity cDNA Kit (Applied
Biosystems, Foster City, CA, USA), according to the
manufacturer’s instructions. The cDNA was diluted 1:10
in RNase-free water. The real-time PCR reaction was
performed using the cDNA samples and the TaqMan
Gene expression assay kit (Applied Biosystems). The
assay ID numbers for the primer pairs and probes were
bcl-2 (Rn 99999125_m1), bax (Rn 01480161-g1), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Rn
99999916-s1). Each assay was run in triplicate on the ABI7500 Fast RT-PCT system. The GAPDH gene was used as
the endogenous control. Relative quantification of gene
expression was determined by the 2-∆∆Ct method.19
Data analysis
Results are presented as mean ± SD or SE per group.
Differences between two groups were compared by the
independent Student’s t-test and differences between
several groups were detected using one-way variance
analysis followed by Tukey’s method for multiple
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comparisons (SPSS version 20.0; SPSS Inc., Chicago, IL,
USA). A p < 0.05 was considered significant.
RESULTS
The effect of BMZ on weight and blood glucose in the
STZ-induced diabetic rats
To investigate the role of BMZ in the development of
STZ-induced diabetes, we generated four different
experimental groups of non-obese rats. Their body
weights were measured before each injection. All of the
animals had similar initial body weights. As shown in
Table 1, no significant changes in body weight were
observed during the experimental period.

The effect of BMZ on islet cell viability
The islets were isolated to investigate the effect of BMZ
on islet cell viability. The purity of the islets was
determined by DTZ staining. Islet viability was determined
by a MatLab analysis following FDA/PI staining.
Average islet viability in the STZ group (63.55 ± 3.90%)
was significantly lower than that in the control and BZM
groups, respectively (83.13 ± 7.12%; 80.21± 5.60%) (p <
0.05) (Figure 2 and Figure 3). BZM alone was not
cytotoxic to the islets. In contrast, BZM protected the
islets from apoptosis by STZ when STZ and BZM were coadministered to the rats (77.94 ± 10.99%) (p < 0.05).

Diabetes was induced by a single STZ injection. The rats
were diabetic 3 days following the STZ injection, as
indicated by an elevated blood glucose level (349.0 ± 24.8
mg glucose/dL, 10 days), compared with the control
group (96.2 ± 2.52) (p < 0.05). Blood glucose levels did not
change significantly in the BMZ group compared with the
control group (98.2 ± 7.1), and they were almost identical
to the control. As shown in Figure 1, blood glucose levels
increased significantly in the STZ+BZM group (407.6 ±
11.0) compared to the control and BZM groups (p < 0.05).
TABLE 1. Body weight changes
First body weight
(g)

Final body weight
(g)

Control

212.00 ± 5.85

219.00 ± 9.20

STZ group

214.60 ± 12.97

205.60 ± 10.62

BZM group

215.40 ± 19.24

220.40 ± 13.11

STZ+BZM group

209.80 ± 13.06

192.20 ± 4.42

Group

Data are mean ± SE of 10 rats per group. No significant
difference was observed between the first and final body
weights of the animals.

FIGURE 1. Blood glucose levels on different days. Values
are mean ± SE of 10 rats per group. The increases in the
blood glucose levels of the STZ and STZ+BZM groups
were all significant compared with the control and BZM
groups after day 4.
Makara J Health Res.

FIGURE 2. Fluorescent microscopic images of living islet
cells stained green with fluorescein diacetate (FDA) and
dead islet cells stained red with propidium iodide (PI).
Images were analyzed with the MatLab program to
determine the percentage of cell viability. At least 3 islet
samples were used for each rat.

FIGURE 3. Islet cell viability values are expressed
according to the results of the MatLab analysis after
FDA/PI staining of the islets. The percentages of viable
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cells in the control, BZM, and STZ+BZM groups were
significantly higher than that in the STZ group (p < 0.05).
Data are mean ± SD. * p < 0.05 vs. control, BZM and
STZ+BZM groups; # p < 0.05 vs. STZ group.
The effect of BMZ on bax and bcl-2 gene expression
levels
The effects of BMZ on bax and bcl-2 gene expression
levels in pancreatic islet cells were determined by RTPCR. As shown in Figure 4a, expression of the proapoptotic bax gene increased significantly in STZ-induced
diabetic rats, as expected (p < 0.05). A decrease in the
bax expression level was detected in the STZ + BZM
group, compared to the STZ group, indicating that BZM
protected the cells from apoptosis by STZ. Furthermore,
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the expression level of the anti-apoptotic bcl-2 gene was
highest in the STZ+BZM group. This increase was
significant vs. the control and the STZ and BZM groups (p
< 0.05). Because apoptosis is mediated by the balance
between the bcl-2 and bax gene expression levels, the
bcl-2/bax ratio determines cell survival or death. Figure
4b shows that the mitochondrial bcl-2/bax gene
expression ratio increased significantly in the BZM group
compared to the control group (p < 0.05), indicating that
BZM promoted an anti-apoptotic effect in the islets. The
ability of BMZ to increase the bcl-2/bax ratio in the
STZ+BZM group compared to the STZ group (p < 0.05)
indicates that it protected the islets from apoptosis by
STZ.

FIGURE 4. Gene expression levels. Bax and bcl-2 gene expression levels in the pancreatic islets were determined by qRTPCR (A). The bcl-2/bax gene expression ratio (B). Data are mean ± SD. of three separate experiments. * p < 0.05 vs. control
group; # p < 0.05 vs. STZ group; ‡ p < 0.05 vs. BZM group.
DISCUSSION
BMZ is a reversible proteasome inhibitor that selectively
inhibits the chymotrypsin-like activity of the proteasome
and is currently clinically used to treat multiple myeloma
and mantle cell lymphoma.9,20 One of the BMZ anticancer
mechanisms is suppression of the NF-κB signaling
pathway.8 Many studies have shown that activation of
NF-κB plays a key role in beta cell destruction and
progression to diabetes,2,3 in contrast to the antiapoptotic function in cancer cells.4,5 This study was
conducted to examine the apoptotic role of BMZ in
pancreatic islets from STZ-induced diabetic rats.
STZ is a toxic glucose and N-acetyl glucosamine analog
that selectively destroys pancreatic beta cells. Thus, it is
widely used to induce type 1 diabetes in experimental
animals.15,21,22 STZ is transported to the pancreatic beta
cells via the low-affinity GLUT 2 glucose transporter,
which preferentially facilitates the uptake of STZ, and
causes DNA alkylation and eventual death of beta
cells.21,22 STZ (single high dose; 35–65 mg/kg rat)
administration depletes the pancreatic beta cells,
resulting in elevated fasting blood glucose levels within
Makara J Health Res.

72 h after administration.21–23 In this study, we observed
a significant increase in blood glucose levels in diabetic
rats compared with the control rats 3 days after STZ
administration. Moreover, we determined a significant
decrease in viability in isolated islets 10 days after
administering the STZ. These data confirm that STZ
destroyed the pancreatic beta cells by increasing blood
glucose levels and decreasing islet cell viability.
Apoptotic cell death is a fundamental mechanism
involved in the loss of pancreatic beta cells. 1 The
biochemical properties of apoptotic cell death include
internucleosomal cleavage of DNA, phosphatidylserine
externalization, and proteolytic cleavage of several
intracellular substrates. Apoptosis is a tightly regulated
process, and the fate of cells depends on the balance
between pro-apoptotic and anti-apoptotic proteins. The
Bcl-2 family of proteins is a critical regulator of apoptotic
cell death. Pro-apoptotic bax gene expression promotes
cell death, whereas anti-apoptotic bcl-2 results in cell
survival. The Bcl-2/bax ratio determines cell death or
survival. Low levels of Bcl-2 and/or high levels of Bax
permeabilize the mitochondria after the apoptotic
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stimulus. Caspase 3 becomes active with the release of
cytochrome c from the intermembrane space into the
cytoplasm followed by the formation of the apoptosome.
Caspase 3 activates the DNase/DNA fragmentation factor
to breakdown nuclear DNA, resulting in DNA
fragmentation and cell death.24 In this study, increased
expression of bax and bcl-2 was observed in the diabetic
rats administered STZ alone. However, because the
increase in bax expression was higher than bcl-2
expression and significantly increased compared to the
control, the decrease in the bcl-2/bax ratio promoted
apoptotic cell death in the rats. This result is compatible
with previous studies showing overexpression of the proapoptotic bax gene and low expression of the antiapoptotic bcl-2 gene in pancreatic beta cells exposed to
STZ.25,26
The main objective of this study was to examine the
apoptotic effect of BMZ on pancreatic islets in STZinduced diabetic rats. BMZ administration alone did not
change the fasting blood glucose level or islet viability,
compared to the control group. In our study, BMZ was
used at a dose of 0.2 mg/kg, which is well tolerated 10,16,27
without any apparent toxicity. Previous studies have
reported that many of the side effects of BMZ, such as
gastrointestinal toxicity, neuropathy, and anemia, are
mild and manageable. BMZ has not been reported to
affect blood glucose, except for the indication that it
should be used with caution in diabetic patients. The
unchanged blood glucose levels observed in the BMZadministered rats were compatible with the fact that
BMZ has no effect on blood glucose in non-diabetic
patients.27 BMZ induces apoptosis in many tumor cells by
decreasing cell viability; thus, it is currently used to treat
multiple myeloma.8 However, the effect of BMZ on the
viability of pancreatic islet cells is not well known. We
observed that BMZ did not change the viability of
pancreatic islet cells. This result is consistent with a study
showing that BMZ does not change the viability of the
MIN6 beta cell line even at a high concentration. 28
Previous studies have reported that other proteasome
inhibitors induce severe apoptosis in mouse and rat beta
insulinoma cell lines.11,12 However, the effect of
proteasome inhibitors on rat islet viability has been
contradictory, as a decrease in viability was observed in
rat islets cultured with MG-132,13 and an increase in
viability was observed with non-toxic concentrations of
celastrol and epoxomicin,14 but lactacystin and ALLN
exerted no visible adverse effects on rat islet cell
viability11,13 and even partially protected against the toxic
effect of pro-inflammatory cytokines such as interleukin1 and interferon.11 Interestingly, we observed that
administering BMZ alone upregulated bcl-2 and
downregulated bax, although the differences were not
significant when compared with the control. However,
these changes in gene expression led to a significant
increase in the bcl-2/bax ratio, indicating that BMZ
administration alone may be anti-apoptotic in pancreatic
Makara J Health Res.

islets, even if it is not reflected in total islet viability. This
result seems contrary to the ability of BMZ to induce
apoptosis, which is widely used in cancer therapy.
However, many studies have shown that BMZ is more
selective in tumor cells than normal cells29,30 and more
effective in hematological cancers than solid tumors29
indicating that BMZ may cause different effects
depending on the tissue and cell types and the stress
conditions.
In this study, we observed that BMZ co-administered
with STZ significantly increased the bcl-2/bax gene
expression ratio and islet viability compared to those in
the control rats, but the same antiapoptotic effect was
not reflected in the blood glucose levels. These results
indicate that BMZ does not completely protect beta cells
from the selective destructive effect of STZ, and possibly
provides partial protection by causing an antiapoptotic
effect in islet cells. A recent study has directly shown that
BMZ prevents the development of diabetes when
administered to pre-diabetic NOD mice.10 NOD mice are
a model of autoimmune diabetes in which no toxin is
administered. Therefore, administering BMZ to NOD
mice in that study prevented hyperglycemia unlike in our
study. In addition, another study demonstrated that
systemic BMZ administration of STZ-induced diabetic
mice delays the rejection of allogeneic islet grafts,
suggesting that BMZ prevents the development of
diabetes by delaying beta cell loss.6 These results may
contribute to the protective effect of BMZ, which we
observed at the total islet viability and gene expression
levels. However, this antiapoptotic protective effect did
not prevent the loss of beta cells enough to block the
development of diabetes. Blood glucose levels are only
affected by beta cell loss, whereas islet viability is the
total viability value of all cell types including alpha and
delta cells in the pancreatic islets. For example, it has
been reported that even STZ administration, which
selectively destroys beta cells, increases the survival
percentage of alpha and delta cells in pancreatic islets. 23
The finding that BMZ causes a similar proliferative effect
by increasing total islet cell viability and bcl-2/bax gene
expression rates may explain why we did not see an
improvement in blood glucose levels. This condition can
also be considered one of several reasons to explain the
conflicting results of other proteasome inhibitors on rat
islet viability.11–14 Therefore, it would be more accurate to
determine individual cell viability for each cell type rather
than total islet cell viability in future diabetes research.
CONCLUSIONS
In conclusion, this study provides evidence that BMZ
induced an antiapoptotic effect by increasing islet cell
viability and the bcl-2/bax ratio in rat pancreatic islets,
although it was inadequate to prevent the loss of beta
cells and the development of STZ-induced diabetes. The
antiapoptotic mechanism of BMZ on pancreatic islet cells
December 2022| Vol. 26 | No. 3
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needs to be further elucidated for each cell type in the
pancreas.
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